A Phase I Sequential Cohort Dose Escalation Trial to Determine the Safety, Tolerability, and MTD of Weekly Administration of GRN163L in Patients With Refractory or Relapsed Solid Tumor Malignancies.
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2014
At a glance
- Drugs Imetelstat (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Geron Corporation
- 19 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jan 2013 Planned End Date changed from 1 Mar 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 24 Jan 2012 Planned end date changed from 1 Jul 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.